Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. DBV Technologies
  6. News
  7. Summary
    DBV   FR0010417345

DBV TECHNOLOGIES

(DBV)
  Report
Real-time Euronext Paris  -  11:35:20 2023-02-03 am EST
2.660 EUR   -1.04%
02/01Telecoms, Natural Resources Lead European Equities Lower in Wednesday Trading
MT
01/27European Equities Move Lower Friday, Set to End Week in Negative Territory
MT
01/23Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Peanut Allergy Pipeline as Novel and Extensive 15+ Therapies Likely to Enter in the Treatment Domain

12/09/2022 | 04:33am EST

DelveInsight's, "Peanut Allergy Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Peanut Allergy Pipeline Report *DelveInsight's Peanut Allergy Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Peanut Allergy. *The leading Peanut Allergy Companies are working such as DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others. *Promising Peanut Allergy Pipeline Therapies include Dupilumab, AR101, ANB020, Viaskin Peanut 50 mcg, and others. *The Peanut Allergy Companies and academics are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Peanut Allergy.

Recent Developmental Activities in the Peanut Allergy Pipeline *DBV is developing the Viaskin technology platform, which delivers biologically active compounds, including allergens, via intact skin. Viaskin is an electrostatic patch, based on Epicutaneous Immunotherapy, or EPIT®, which administers an allergen directly onto the superficial layers of the skin to activate the immune system by specifically targeting antigen-presenting cells without allowing passage of the antigen into the bloodstream. It is currently in preregistration stage of development. *Dupilumab is a IL-4R Antibody that is being developed by Regeneron Pharmaceuticals in collaboration with Sanofi for the treatment of Peanut Allergy. It is currently in phase II stage of development. *CNP-201 is a biodegradable nanoparticle encapsulating peanut protein. It has the potential to treat patients with peanut allergy by reducing the need for strict peanut avoidance and reducing the potentially fatal health risks associated with peanut allergy. It is currently in phase I/II stage of development.

Request a sample and discover the recent advances in Peanut Allergy Treatment Drugs @ Peanut Allergy Pipeline Outlook Report

Peanut Allergy Overview

A peanut allergy is a reaction that occurs when your body mistakenly identifies peanuts as harmful substances. When you eat peanuts or food containing peanuts, your immune system -the body's natural defense system that fights infections and diseases-overreacts and can cause a serious, even life-threatening response. Symptoms of peanut allergy can range from mild to severe. If you have a mild reaction, you may get a stomachache, a runny nose, itchy eyes, hives, or tingling in your lips or tongue. Your symptoms may start from within a few minutes to a few hours after eating peanuts or peanut products.

Peanut Allergy Emerging Drugs Profile *Viaskin Peanut: DBV Technologies *Dupilumab: Regeneron Pharmaceuticals/Sanofi *CNP-201: Cour Pharmaceutical

Peanut Allergy Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Peanut Allergy. The companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. preregistration include, DBV Technologies.

Get an overview of the Peanut Allergy Pipeline Report @ Peanut Allergy Ongoing Clinical Trials Analysis

Scope of the Peanut Allergy Pipeline Report *Coverage- Global *Peanut Allergy Companies are working such as DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others. *Peanut Allergy Pipeline Therapies include Dupilumab, AR101, ANB020, Viaskin Peanut 50 mcg, and others. *Peanut Allergy Emerging Therapies, Unmet Needs, Analyst Views

Table of Content *Introduction *Peanut Allergy Executive Summary *Peanut Allergy: Overview *Peanut Allergy Pipeline Therapeutics *Peanut Allergy Therapeutic Assessment *Late Stage Products (Preregistration) *Viaskin Peanut: DBV Technologies *Drug profiles in the detailed report..... *Mid Stage Products (Phase II) *Dupilumab: Regeneron Pharmaceuticals *Drug profiles in the detailed report..... *Early Stage Products (Phase I/II) *CNP-201: Cour Pharmaceutical *Drug profiles in the detailed report..... *Preclinical and Discovery Stage Products *Peanut-NE01 vaccine: BlueWillow Biologics *Drug profiles in the detailed report..... *Inactive Products *Peanut Allergy Key Companies *Peanut Allergy Key Products *Peanut Allergy- Unmet Needs *Peanut Allergy- Market Drivers and Barriers *Peanut Allergy- Future Perspectives and Conclusion *Peanut Allergy Analyst Views *Peanut Allergy Key Companies *Appendix

Key Questions

Current Treatment Scenario and Emerging Therapies: *How many companies are developing Peanut Allergy drugs? *How many Peanut Allergy drugs are developed by each company? *How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peanut Allergy? *What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peanut Allergy therapeutics? *What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? *What are the clinical studies going on for Peanut Allergy and their status? *What are the key designations that have been granted to the emerging drugs?

For further information on the Peanut Allergy Pipeline therapeutics, reach out to Peanut Allergy Treatment Landscape

Media Contact

Company Name: DelveInsight LLP

Contact Person: Yash Bhardwaj

Email: ybhardwaj@delveinsight.com

Phone: 09193216187

Address:304 S. Jones Blvd #2432,

City: Las Vegas

State: United States

Country: India

Website: https://www.delveinsight.com/

Source: www.abnewswire.com

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
ALLERGY THERAPEUTICS PLC 0.00% 6.25 Delayed Quote.0.00%
ASTELLAS PHARMA INC. -0.55% 1889.5 Delayed Quote.-5.83%
DBV TECHNOLOGIES -1.04% 2.66 Real-time Quote.-15.45%
REGENERON PHARMACEUTICALS, INC. 4.25% 783.13 Delayed Quote.4.12%
SANOFI -1.88% 85.14 Real-time Quote.-5.23%
All news about DBV TECHNOLOGIES
02/01Telecoms, Natural Resources Lead European Equities Lower in Wednesday Trading
MT
01/27European Equities Move Lower Friday, Set to End Week in Negative Territory
MT
01/23Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
GL
01/23Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AQ
01/23European Equities Rise as Consumer Confidence Grows
MT
01/18Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading
MT
01/13European Equities Rise in Friday Trading, ADRs End Week Up 2%
MT
01/12European Equities Led Higher by Financial, Telecoms Stocks
MT
01/11Pharma Stocks Pull European Equities Lower in Wednesday Trading
MT
01/05Pharma Stocks Lead European Equities Lower in Thursday Trading
MT
More news
Analyst Recommendations on DBV TECHNOLOGIES
More recommendations
Financials
Sales 2022 7,04 M 7,64 M 7,64 M
Net income 2022 -75,3 M -81,7 M -81,7 M
Net cash 2022 156 M 170 M 170 M
P/E ratio 2022 -3,05x
Yield 2022 -
Capitalization 250 M 271 M 271 M
EV / Sales 2022 13,3x
EV / Sales 2023 28,5x
Nbr of Employees 85
Free-Float 91,6%
Chart DBV TECHNOLOGIES
Duration : Period :
DBV Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DBV TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 2,66 €
Average target price 5,64 €
Spread / Average Target 112%
EPS Revisions
Managers and Directors
Daniel TassÚ Chief Executive Officer & Executive Director
SÚbastien Robitaille Chief Financial Officer
Michel de Rosen Non-Executive Chairman
Pharis Mohideen Chief Medical Officer
Pascal Wotling Chief Technical Operations & Quality Officer
Sector and Competitors